NDAINJECTIONINJECTABLE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDELTRA-TBA (prednisolone tebutate) is an injectable corticosteroid approved in 1956 for inflammatory and immunosuppressive indications. It is administered via injection and works through glucocorticoid receptor binding to reduce inflammation and immune responses. The drug treats a range of conditions where systemic corticosteroid therapy is indicated.
LOE Approaching
Product is approaching loss of exclusivity with low linked job count, indicating a mature, maintenance-focused team with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYDELTRA-TBA offers minimal career momentum as a legacy product with zero linked job postings and approaching loss of exclusivity. Roles on this product focus on defending market position and managing profitability rather than growth and innovation.
Brand ManagerProduct Manager
Worked on HYDELTRA-TBA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.